15 years experienced cancer research biotech
We are a biotechnological research and CRO company which aims to use scientifically founded strategies to identify and validate new drug targets and use preclinical models for testing and developing mainly new anticancer and other anti-disease technologies and treatments.
Our company can fast, cost-effective and accurate prove a developmental concept of your research.
about us
research& development
DRUG DEVELOPMENT
Given the still dismal overall prognosis for cancer patients, the need is evident to discover and develop novel targeted and personalized anticancer therapies, where we are contributing in numerous self- and grant- funded projects
PDTX MODELS
We successfully developed our system to establish, maintain and archive PDTX models in order to provide numerous options to our partners to use the most reliable preclinical models for in vivo drug testing
TARGET IDENTIFICATION
KINETO Lab is discovering novel molecular targets of tumor cells, leading to effective therapeutics development. New homing domains can selectively deliver the drugsh to its site of action
ANTIBODY DEVELOPMENT
KINETO Lab intends to expand its existing tissue culture and animal- based infrastructure on the way that it can continually be able to isolate larger amount of antibodies
DIAGNOSTICS
We are developing detection methods and devices by which it is possible to detect and capture a specific cell type using combined markers in order to improve cancer diagnosis and prognosis
PARTNERSHIP
ARE YOU WILLING TO HAVE A TRUSTFUL PARTNER AND MAKE SUCCESSFUL COLLABORATION?
If you would like to become our partner, please contact us.
SERVICES
KINETO Lab is an acknowledged expert providing tailored and unique methods to identify and validate new drug targets and to evaluate in vitro and in vivo activity of anticancer drugs in the preclinical drug discovery.
IN VITRO
KINETO Lab offers and provides wide range of in vitro preclinical services on various tumor models which allow you to determine the activity of your compound, select the best compound and develop your therapeutics
EX VIVO
We provide tumor and organ samples, which can be routinely processed, characterized and evaluated with validated pathological, biochemical and histological analysis methods supporting your research
IN VIVO
Demonstrating the antitumor activity of a novel agent in animal models is important step in preclinical drug development, therefore we propose in vivo preclinical models which can be used per se or associated with imaging modalities to permit the evaluation of the efficacy of newly developed therapeutics
immuno-oncology
In order to study immunology aspects of cancer KINETO Lab provides in vitro and in vivo models suitable to prove your developmental concept
CONSULTANCY
Nowadays, polyhistorians in the classical sense no longer work effectively. Good quality scientific work requires cooperation between representatives of different disciplines.
We can provide you with assessment,
advice and ideas on biological issues
If you are a chemistry-related research laboratory involved in drug development, and if you are planning a new project, or already have ongoing projects where the biological aspects of the topic and feasibility and rationality arise, we can provide you with assessment, advice and ideas on biological issues to put your research on the scientific or business map.
CONSULTANCY
We can provide you with assessment,
advice and ideas on biological issues
PRODUCTS
Additionally, we offer different samples from in vitro and in vivo experiments, for your further analyses.
We can prepare and ship different samples from in vitro and in vivo experiments, for your further analyses.
Additionally, we can perform the molecular biology analysis service in our lab, providing you final results.
NEWS
16/04/2024
The study about potential clinical benefits of combining KRAS-G12C inhibitors with farnesyltransferase inhibitors was presented at AACR Annual Meeting
At AACR Annual Meeting which held in San Diego Convention Center, San Diego, California, USA, from April 5th to 10th, 2024, our chief scientific officer Dr. József Tóvári presented the poster with the title „Antitumor effects of KRAS-G12C inhibitors can be improved by farnesyltransferase inhibitors in preclinical models”.
07/03/2024
Published a study about a gluing docking method for finding small molecules that bind to both the GAP and the mutated KRAS molecules
10/02/2023
Published a new study on targeting KRAS with combination of KRAS-G12C and Farnesyl-transferase inhibitors in British Journal of Cancer
05/01/2024
Attending NEXGEN-PD consortium meeting on January 11th to 12th, 2024 in Salzburg, Austria
CONTACTS
If you have any question regarding our research, services or PDTX models, and if you want to get in touch with us, fill the form or send us an e-mail on info@kinetolab.hu.
We are always open for your CV and application in case you would like to work in an innovative, dynamically growing cancer research-related biotech company in the future. If you think you could fit in KINETO Lab’s team, please contact us.
